
May 25, 2026
CLVT: Free Cash Flow May Offset AI And Portfolio Execution Risks
Analysts have adjusted their price targets for Clarivate, reflecting concerns about potential disruptions from AI and uncertainties surrounding its planned sale of the Life Sciences and Healthcare unit. Despite these challenges, there are indications of strong free cash flow and optimistic growth projections.Recent evaluations of Clarivate reveal a cautious outlook, with price targets now ranging between $2.40 and $6. Analysts have maintained their ratings but expressed a more conservative view









